As shown in Fig. 1B, Asian patients (China Pan-Cancer, OrigiMed, Nature 2022) had the highest incidence of MET fusions, at approximately 1.05%, which was much higher than the second highest incidence (MSK MetTropism, MSK, Cell 2021, incidence of MET fusions: 0.22%). Here, MET is linked to cancer.